University of New Mexico Center for Molecular Discovery

描述（由申请人提供）：新墨西哥州大学分子发现中心（UNMCMD）是一个专注于多重HT流式细胞术的专业中心，继续开展新墨西哥州分子库筛选中心（U 54 MH 074425）和生物医学研究合作伙伴关系（R24 EB 000264）。我们发明了HT流式细胞仪平台HyperCyt <$并将其引入MLSCN。我们的发现工具能够对配体结合和/或蛋白质-蛋白质相互作用（PPI）进行均相分析，进行多参数或高含量分析，以及对细胞反应或结合进行实时测量。我们在11分钟内分析了384孔板。在MLSMR上完成的筛选产生了细胞（分子和表型）和基于珠的靶标的探针。 经验表明，大多数靶标可以以流式细胞术兼容的格式显示。通过创建颗粒的悬浮阵列，靶可以高度多重化或在复杂的细胞群体上进行，而不会损失通量。我们的团队在全球范围内发表了超过100篇出版物，超过20项发明，关于流式细胞术和虚拟筛选的书籍，以及超过100次口头宣传演讲。我们拥有超过150年的流式细胞术经验，包括生物化学、细胞和分子生物学方面的应用，同时也是酵母靶点的双重专业化公司。我们中的一位拥有超过20年的工业高温超导经验，用于超过150种新型靶。我们的核心能力包括：1）有效的推广和合作伙伴关系; 2）识别和开发创新目标; 3）实施外部初级和二级检测; 4）多重目标的生产模式筛选; 5）数据上传到PubChem。我们在将显像剂和同位素整合到MLPCN中方面具有独特的优势。我们希望在我们的所有活动中进行创新。通过推广，我们将创建和维护MLPCN的多重检测管道。试验开发将包括但不限于酵母、真核和分析靶标。我们将建立机制，优先考虑和实施MLPCN的目标和探针分析伙伴关系，包括化合物溶解度。我们将创建工具来分析和可视化多路HTS数据集。我们将加强和维护与目标供应商和化学专业中心建立网络的协作工具，以进行筛选和随访，并在MLPCN内进行协作分析和化合物溶解度。One Center Driven Project专注于通过利用我们中心沿着的商业合作伙伴最近的设计和工程突破来提高通量（从384孔格式到1536孔格式）并改善HT流式细胞术的性能。通过合作推广，我们将评估洛斯阿拉莫斯国家实验室P41国家流式细胞术资源中出现的新发现技术。第二个中心驱动的项目开发了一个工具箱，用于酵母靶点，如PPI，途径分析，蛋白质-DNA相互作用，以及通用的多重酵母双杂交发现平台。

DESCRIPTION (provided by applicant): The University of New Mexico Center for Molecular Discovery (UNMCMD), a specialty center focusing on multiplexed, HT flow cytometry, continues the New Mexico Molecular Libraries Screening Center (U54MH074425) and a Biomedical Research Partnership (R24EB000264). We invented the HT flow cytometry platform HyperCyt¿ and introduced it to the MLSCN. Our discovery tools enable homogeneous analysis of ligand binding and/or protein-protein interaction (PPI), multiparameter or high content analysis, and real-time measurements of cell response or binding. We analyze a 384 well plate in 11 min. Completed screens on the MLSMR have produced probes for cell (molecular and phenotypic) and bead-based targets. Experience indicates that most targets can be displayed in a flow cytometry compatible format. By creating a suspension array of particles, targets can be highly multiplexed or performed on complex cell populations without loss of throughput. Our team has produced >100 publications, >20 inventions, books on Flow Cytometry for Biotechnology and Virtual Screening, and >100 oral outreach presentations world-wide. We have >150 years of flow cytometry experience that includes applications in biochemistry, and cell and molecular biology compatible with a dual specialization in yeast targets. One of us has >20 years of experience in industrial HTS for >150 novel targets. We have core capabilities that include 1) effective outreach and partnership; 2) identifying and developing innovative targets; 3) implementing external primary and secondary assays; 4) production mode screening of multiplexed targets; and 5) data upload to PubChem. We are uniquely positioned to integrate imaging agents and isotopes into the MLPCN. We intend to innovate in all of our activities. Through outreach, we will create and maintain a pipeline of multiplex assays for the MLPCN. Assay development will include, but not be limited to, yeast, eukaryotic, and profiling targets. We will create mechanisms to prioritize and implement partnerships for profiling targets and probes, including compound solubility, for the MLPCN. We will create tools to analyze and visualize multiplex HTS data sets. We will enhance and maintain collaborative tools for networking with target providers and Chemistry Specialty Centers for screening and follow up, and within the MLPCN for collaborative profiling and compound solubility. One Center Driven Project focuses on increasing throughput (from 384 to 1536 well format) and improving the performance of HT flow cytometry by exploiting recent design and engineering breakthroughs in our Center along with commercial partners. Through collaborative outreach, we will evaluate new discovery technologies emerging from the Los Alamos National Labs P41 National Flow Cytometry Resource. A second Center Driven Project develops a toolbox for yeast targets such as PPI, Pathway analysis, protein-DNA interactions, and a universal, multiplex yeast two-hybrid discovery platform.